Radar on Specialty Pharmacy

Study Shows High Adherence in People on CDK 4/6 Inhibitors

Since 2015, three cyclin-dependent kinase (CDK) 4/6 inhibitors have come onto the U.S. market as treatments for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or me...
0 Comments
© 2025 MMIT

CMS OKs Copay Accumulators For Drugs With No Generics

In a reverse course from its stance a year ago, CMS recently finalized a rule allowing nongrandfathered individual and group market plans to not count manufacturer copayment assistance toward members’ annual deduc...
0 Comments
© 2025 MMIT

Questions Surround Some DMD Drugs; More Near U.S. Market

Since 2016, the FDA has approved a handful of therapies to treat Duchenne muscular dystrophy (DMD). But some uncertainty exists over their effectiveness, in addition to concerns about their costs. Additional product...
0 Comments
© 2025 MMIT

Source: Pandemic Poses ‘Major Disruption’ to My Cancer Care

A longtime pharma industry expert spoke with AIS Health about their experience as someone with cancer during a pandemic. They asked to remain unidentified: AIS Health: What kind of cancer do you have, and when we...
0 Comments
© 2025 MMIT

New FDA Specialty approvals

✦ May 6: The FDA gave accelerated approval to Novartis Pharmaceuticals Corp.’s Tabrecta (capmatinib) for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesen...
0 Comments
© 2025 MMIT

News Briefs

✦ The Association for Accessible Medicines (AAM) filed an amicus brief May 13 in support of the Biologics Price Competition and Innovation Act of 2009 (BPCIA) remaining law if the Affordable Care Act (ACA) is inva...
0 Comments
© 2025 MMIT

Groups Call on CMS to Modify Medicare Home Infusion Benefit

As people are urged to stay home during the COVID-19 pandemic, CMS has been relaxing a series of health care service policies in support of this need. But one change it hasn’t made is to allow home infusion to be ...
0 Comments
© 2025 MMIT

Amid COVID-Spurred Shifts in Home Infusion, Model May Morph

With numerous hospitals focused on the COVID-19 pandemic and many areas under stay-at-home mandates, home infusion is more important than ever. Changes within the industry already have been seen, and the current sit...
0 Comments
© 2025 MMIT

Biosimilars May Be Impacting Payers’ Medical Benefit Spend

Over the past decade, commercial per-member per-month (PMPM) drug spend under the medical benefit has almost doubled, according to Magellan Rx Management, a division of Magellan Health, Inc. The company just rele...
0 Comments
© 2025 MMIT

Some Payers Say They May Allow Off-Label Use of Jelmyto

On April 15, the FDA approved the first drug for patients with low-grade upper tract urothelial cancer, UroGen Pharma Ltd.’s Jelmyto (mitomycin). It offers patients a nonsurgical option for a condition that often ...
0 Comments
© 2025 MMIT